ArticleOcular oncology and pathology2018
Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma.
Article in Ocular oncology and pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Prognosis and determinants of survival after orbital exenteration for conjunctival melanoma: Experiences from a Dutch Referral Centre.Acta ophthalmologica · 2026Article
- Emerging Techniques in the Treatment of Conjunctival Melanoma.Current ophthalmology reports · 2025Review
- Subepithelial Lesions of the Ocular Surface: A Review.Current ophthalmology reports · 2025Review
- Conjunctival melanoma: comprehensive insights into clinical features, genetic alterations, and modern treatment approaches.Pathology oncology research : POR · 2025Review
- Conjunctival Melanoma: A Clinical Review and Update.Cancers · 2024Review
- Review
- Targeting β-catenin using XAV939 nanoparticle promotes immunogenic cell death and suppresses conjunctival melanoma progression.International journal of pharmaceutics · 2023Article
- Annulus-shaped I-125 plaque brachytherapy for conjunctival melanoma.American journal of ophthalmology case reports · 2022Article
- New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.International journal of molecular sciences · 2022Review
- Small but Challenging Conjunctival Melanoma: New Insights, Paradigms and Future Perspectives.Cancers · 2021Review
- High-Dose-Rate Interstitial Brachytherapy (Interventional Radiotherapy) for Conjunctival Melanoma with Orbital Extension.Ocular oncology and pathology · 2021Article
- Efficacy of immune checkpoint inhibitors in different types of melanoma.Human vaccines & immunotherapeutics · 2021Article
- Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.International ophthalmology clinics · 2020Article
- Immune check point inhibitors for ocular adnexal and periocular tumors.Taiwan journal of ophthalmologyReview
- Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma.Journal of ophthalmic & vision researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of patients with diffuse invasive conjunctival melanoma focuses on local tumor control and screening for metastasis. Despite the lack of consensus on the benefit of sentinel lymph node biopsy for these neoplasms, the information obtained by histopathology is useful for tumor staging and treatment planning. Due to the lack of evidence of survival improvement, orbital exenteration is being performed with diminishing frequency. We describe a patient with diffuse invasive conjunctival melanoma and lymph node involvement treated by tumor debulking, brachytherapy (custom unshielded radioactive device), and adjuvant ipilimumab who has had a favorable outcome without emergence of local tumor relapse or distant metastasis during 16 months of follow up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.